FXR agonists, which have recently been evaluated in the treatment of various chronic liver diseases and have been shown to reduce inflammation and fibrosis, have also shown promise in reducing PH, although are also associated with significant side effects and have a black box warning since they have been shown to increase the risk of decompensation in patients with moderate to severe PBC. The gene discussed is NR1H4; the disease is primary biliary cholangitis.